Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer.

They send 2 press release on this morning regarding the development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation”

These 2 good news from $14.90 to $28.63 in less than 1 hour.

Here is the link of their website where you can find the press release.

He close his day at $30.43. Here is the graph of the complete first day.

Here is the details of what he did on second day.
Start at $31.32, and close at $34.655 for a +13.88%